

# Tim F Greten

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2780793/publications.pdf>

Version: 2024-02-01

288  
papers

47,939  
citations

8159

76  
h-index

1745

212  
g-index

310  
all docs

310  
docs citations

310  
times ranked

48980  
citing authors

#	ARTICLE	IF	CITATIONS
1	The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma. <i>Gut</i> , 2022, 71, 1161-1175.	6.1	60
2	A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma. <i>Oncologist</i> , 2022, 27, e273-e285.	1.9	22
3	MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays. <i>Cell Reports Methods</i> , 2022, 2, 100136.	1.4	8
4	NAFLD indirectly impairs antigen-specific CD8+ T cell immunity against liver cancer in mice. <i>IScience</i> , 2022, 25, 103847.	1.9	12
5	The gut-liver axis: host microbiota interactions shape hepatocarcinogenesis. <i>Trends in Cancer</i> , 2022, 8, 583-597.	3.8	22
6	Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. <i>Journal of Hepatology</i> , 2022, 77, 748-760.	1.8	57
7	Innate lymphoid cells at the crossroads of innate and adaptive immunity. <i>Hepatology</i> , 2022, 76, 903-905.	3.6	0
8	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. <i>Hepatology</i> , 2021, 73, 158-191.	3.6	235
9	Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice. <i>Gastroenterology</i> , 2021, 160, 331-345.e6.	0.6	46
10	Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis. <i>Journal of Hepatology</i> , 2021, 74, 700-715.	1.8	60
11	Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. <i>Cellular and Molecular Immunology</i> , 2021, 18, 112-127.	4.8	159
12	CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2021, 74, 1145-1154.	1.8	76
13	Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma. <i>Cancer Discovery</i> , 2021, 11, 1248-1267.	7.7	117
14	Hydroxychloroquine can impair tumor response to anti-PD1 in subcutaneous mouse models. <i>IScience</i> , 2021, 24, 101990.	1.9	11
15	Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 1166-1178.	2.3	15
16	Gut Microbiome and Liver Cancer. <i>Physiology in Health and Disease</i> , 2021, , 199-255.	0.2	0
17	Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 1455.	5.8	96
18	MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target. <i>Cellular Immunology</i> , 2021, 361, 104295.	1.4	28

#	ARTICLE	IF	CITATIONS
19	Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 507-512.	1.8	8
20	Activating Mucosal-Associated Invariant T Cells Induces a Broad Antitumor Response. <i>Cancer Immunology Research</i> , 2021, 9, 1024-1034.	1.6	29
21	Evaluating the impact of hydroxychloroquine on mouse lymphocyte proliferation and cytokine production in vivo and in vitro. <i>STAR Protocols</i> , 2021, 2, 100517.	0.5	0
22	Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2021, 75, 1397-1408.	1.8	133
23	Hepatocellular Carcinoma – Origins and Outcomes. <i>New England Journal of Medicine</i> , 2021, 385, 280-282.	13.9	60
24	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
25	Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 293-313.	8.2	428
26	Transplant Oncology in Primary and Metastatic Liver Tumors. <i>Annals of Surgery</i> , 2021, 273, 483-493.	2.1	33
27	Engineered Anti-EGPC3 Immunotoxin, HN3-ABD-20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention. <i>Hepatology</i> , 2020, 71, 1696-1711.	3.6	42
28	Loss of myeloid-specific lamin A/C drives lung metastasis through Gfi1 and C/EBPβ-mediated granulocytic differentiation. <i>Molecular Carcinogenesis</i> , 2020, 59, 679-690.	1.3	3
29	Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database Analysis. <i>Hepatology Communications</i> , 2020, 4, 1541-1551.	2.0	87
30	Microbiome genomics for cancer prediction. <i>Nature Cancer</i> , 2020, 1, 379-381.	5.7	14
31	Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. <i>Gastroenterology</i> , 2020, 158, 2250-2265.e20.	0.6	97
32	Gut microbiome in HCC – Mechanisms, diagnosis and therapy. <i>Journal of Hepatology</i> , 2020, 72, 230-238.	1.8	206
33	Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2318-2326.	3.2	54
34	Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma. <i>Journal of Liver Cancer</i> , 2020, 20, 1-16.	0.3	3
35	A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, e349-e360.	1.0	31
36	Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer. <i>Cancer Cell</i> , 2019, 36, 418-430.e6.	7.7	433

#	ARTICLE	IF	CITATIONS
37	The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 599-608.	2.0	97
38	The effects of platelet accumulation in fatty liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 393-394.	8.2	11
39	Gender disparity in HCC: Is it the fat and not the sex?. <i>Journal of Experimental Medicine</i> , 2019, 216, 1014-1015.	4.2	14
40	Immunotherapy: Current Status and Future Perspectives. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1030-1040.	1.1	24
41	Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy. <i>Hepatology</i> , 2019, 70, 1437-1442.	3.6	104
42	Combined locoregional-immunotherapy for liver cancer. <i>Journal of Hepatology</i> , 2019, 70, 999-1007.	1.8	146
43	Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization. <i>International Journal of Biological Sciences</i> , 2019, 15, 2654-2663.	2.6	18
44	Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer. <i>Hepatology</i> , 2019, 69, 2048-2060.	3.6	77
45	Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites after Hepatic Drug-Eluting Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 19-22.	0.2	4
46	Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 156, 510-524.	0.6	179
47	Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, 449-457.	1.8	102
48	Immune Therapies. <i>Molecular and Translational Medicine</i> , 2019, , 239-253.	0.4	1
49	Immune checkpoint inhibition (ICI) in combination with SBRT in patients with advanced pancreatic adenocarcinoma (aPDAC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 192-192.	0.8	3
50	Hepatocellular carcinoma (HCC) survival by etiology: A SEER-Medicare database analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 201-201.	0.8	9
51	Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 336-336.	0.8	41
52	A phase I/II study of pexa-vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer: Safety report.. <i>Journal of Clinical Oncology</i> , 2019, 37, 646-646.	0.8	8
53	Abstract 4500: Mechanisms of tumor-associated myeloid cells in modulating host immune microenvironment and metastatic progression. , 2019, , .		0
54	Abstract 1526: Colitis promotes intrahepatic cholangiocarcinoma via gut microbiome dependent, CXCL1/CXCR2 mediated MDSC accumulation. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
55	Abstract CN07-02: Immunotoxins targeting GPC3 for liver cancer. , 2019, , .		0
56	Abstract 2311: Analysis of glypican 3-targeted chimeric antigen receptor T cells in hepatocellular carcinoma cell and mouse models. , 2019, , .		0
57	The ABC of adaptive immunity in liver cancer. <i>Hepatology</i> , 2018, 68, 777-779.	3.6	1
58	Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. <i>Hepatology</i> , 2018, 68, 127-140.	3.6	231
59	Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients. <i>Clinical Cancer Research</i> , 2018, 24, 2859-2872.	3.2	40
60	CDK20 inhibition and immune checkpoint blockade: bringing cancer biology and tumour immunology together to develop novel treatment options for HCC. <i>Gut</i> , 2018, 67, 783-784.	6.1	7
61	A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , 2018, 67, 1127-1131.	3.6	70
62	Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes. <i>FEBS Journal</i> , 2018, 285, 752-762.	2.2	43
63	Targets for immunotherapy of liver cancer. <i>Journal of Hepatology</i> , 2018, 68, 157-166.	1.8	129
64	Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481880808.	1.4	10
65	Development of shellfish allergy after exposure to dual immune checkpoint blockade. <i>Hepatic Oncology</i> , 2018, 5, HEPO2.	4.2	3
66	Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. <i>Science</i> , 2018, 360, .	6.0	931
67	Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1305-1315.	2.0	93
68	Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. <i>Cell Death and Disease</i> , 2018, 9, 620.	2.7	90
69	miR-130a and miR-145 reprogram Gr-1+CD11b+ myeloid cells and inhibit tumor metastasis through improved host immunity. <i>Nature Communications</i> , 2018, 9, 2611.	5.8	29
70	Establishment of Orthotopic Liver Tumors by Surgical Intrahepatic Tumor Injection in Mice with Underlying Non-Alcoholic Fatty Liver Disease. <i>Methods and Protocols</i> , 2018, 1, 21.	0.9	14
71	Mitophagy in Intestinal Epithelial Cells Triggers Adaptive Immunity during Tumorigenesis. <i>Cell</i> , 2018, 174, 88-101.e16.	13.5	93
72	Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 536-554.	8.2	158

#	ARTICLE	IF	CITATIONS
73	Cytokine-induced killer cells recruit myeloid derived suppressor cells in HCC, which can be targeted by a PDE5 inhibitor. <i>Journal of Hepatology</i> , 2018, 68, S95-S96.	1.8	1
74	Abstract 1728: Nonalcoholic steatohepatitis (NASH) impairs treatment of intrahepatic metastases with CD4+ T cell dependent RNA vaccine. <i>Cancer Research</i> , 2018, 78, 1728-1728.	0.4	4
75	Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 365-365.	0.8	0
76	An open label phase 1b/2 trial of TRC105 and sorafenib in patient with advanced/metastatic hepatocellular carcinoma (HCC) (NCT01806064).. <i>Journal of Clinical Oncology</i> , 2018, 36, 301-301.	0.8	1
77	Abstract 2549: Development of CAR T-cell therapy targeting glypican-3 in liver cancer. , 2018, , .		0
78	Abstract A02: Gut microbiome controls growth of liver tumors. , 2018, , .		1
79	Specific immunotherapy in hepatocellular cancer: A systematic review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 339-351.	1.4	6
80	Shall we blame CD4 T cells for everything?. <i>Gut</i> , 2017, 66, 763-764.	6.1	0
81	Regorafenib as second-line therapy in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 141-142.	8.2	26
82	Tumor regulation of the tissue environment in the liver. , 2017, 173, 47-57.		68
83	Commensal bacteria (ab)use CD8 <sup>+</sup> T cells to induce insulin resistance. <i>Science Immunology</i> , 2017, 2, .	5.6	3
84	Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 4633-4641.	3.2	68
85	Immunosuppressive cell death in cancer. <i>Nature Reviews Immunology</i> , 2017, 17, 401-401.	10.6	19
86	Treating Hepatobiliary Cancer: The Immunologic Approach. <i>Digestive Diseases</i> , 2017, 35, 390-396.	0.8	7
87	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017, 357, 409-413.	6.0	4,945
88	Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma. <i>Digestion</i> , 2017, 96, 1-4.	1.2	43
89	Systematic evaluation of immune regulation and modulation. , 2017, 5, 21.		20
90	Does CSF1R Blockade Turn into Friendly Fire?. <i>Cancer Cell</i> , 2017, 32, 546-547.	7.7	3

#	ARTICLE	IF	CITATIONS
91	Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 545-551.	1.8	624
92	Cellular senescence associated immune responses in liver cancer. <i>Hepatic Oncology</i> , 2017, 4, 123-127.	4.2	15
93	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. , 2017, 5, 93.		56
94	A pilot study of immune checkpoint inhibition in combination with radiation therapy in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15786-e15786.	0.8	8
95	Immune Suppressor Mechanisms in HCC. , 2017, , 121-135.		0
96	Tremelimumab: A monoclonal antibody against CTLA-4”In combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 88-88.	0.8	0
97	Abstract 936: Single cell analysis reveals cancer stem cell heterogeneities in hepatocellular carcinoma. <i>Cancer Research</i> , 2017, 77, 936-936.	0.4	1
98	Abstract 3057: Gut microbiome controls liver metastasis. , 2017, , .		0
99	Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. <i>Cancer</i> , 2016, 122, 1757-1765.	2.0	245
100	The case for immune”based approaches in biliary tract carcinoma. <i>Hepatology</i> , 2016, 64, 1785-1791.	3.6	25
101	Pancreatic Squamous Cell Carcinoma. <i>Pancreas</i> , 2016, 45, 1432-1437.	0.5	43
102	Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750”an antisense oligonucleotide against eIF4E”in combination with irinotecan in solid tumors and irinotecan”refractory colorectal cancer. <i>International Journal of Cancer</i> , 2016, 139, 1648-1657.	2.3	55
103	Future Therapy of Cholangiocarcinoma. <i>Visceral Medicine</i> , 2016, 32, 431-433.	0.5	0
104	NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. <i>Nature</i> , 2016, 531, 253-257.	13.7	552
105	Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression. <i>Cancer Cell</i> , 2016, 30, 533-547.	7.7	397
106	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. <i>Nature Communications</i> , 2016, 7, 12150.	5.8	2,076
107	Editorial: ”Invisible”MDSC in tumor-bearing individuals after antibody depletion: fact or fiction?. <i>Journal of Leukocyte Biology</i> , 2016, 99, 794-794.	1.5	12
108	A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. <i>Investigational New Drugs</i> , 2016, 34, 168-175.	1.2	40

#	ARTICLE	IF	CITATIONS
109	Abstract A195: Tremelimumab activates CD4 and CD8+ T cells in patients with hepatocellular carcinoma. , 2016, , .		2
110	Programmed death-1 blockade in mismatch repair deficient colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 103-103.	0.8	50
111	Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology.. Journal of Clinical Oncology, 2016, 34, 3003-3003.	0.8	24
112	Tremelimumab: A monoclonal antibody against CTLA-4 In combination with subtotal ablation (trans) Tj ETQqO O O rgBT /Overlock 10 patients with hepatocellular carcinoma (HCC) and biliary tract carcinoma (BTC).. Journal of Clinical Oncology, 2016, 34, 4073-4073.	0.8	7
113	PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.. Journal of Clinical Oncology, 2016, 34, 195-195.	0.8	39
114	A pilot study of AMP-224, a PD-L2 Fc fusion protein, in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 560-560.	0.8	19
115	A pilot study of immune checkpoint inhibition (tremelimumab and/or MEDI4736) in combination with radiation therapy in patients with unresectable pancreatic cancer.. Journal of Clinical Oncology, 2016, 34, TPS470-TPS470.	0.8	1
116	Abstract A132: Nonalcoholic fatty liver disease causes selective CD4+ lymphocytes loss and promotes hepatocarcinogenesis. , 2016, , .		1
117	Abstract 2653: Tremelimumab plus tumor ablation for patients with hepatocellular carcinoma: Clinical results, immunomonitoring analysis of peripheral T cells and tumor biopsies. , 2016, , .		0
118	Abstract 3421: Epidemiology and survival in patients with extragastric signet ring carcinoma. , 2016, , .		0
119	Abstract 5015: Pretreatment carcinoembryonic antigen levels predict survival in patients with rectal adenocarcinoma. , 2016, , .		0
120	2259 Tremelimumab - A monoclonal antibody against CTLA-4 - in combination with local tumor ablation (TACE or RFA) in patients with hepatocellular carcinoma (HCC). European Journal of Cancer, 2015, 51, S419.	1.3	0
121	Tumor-induced CD11b <sup>+</sup> Gr <sup>1</sup> myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner. European Journal of Immunology, 2015, 45, 1148-1158.	1.6	10
122	Immune play: defending the liver. Hepatic Oncology, 2015, 2, 15-18.	4.2	0
123	A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib. United European Gastroenterology Journal, 2015, 3, 453-461.	1.6	36
124	Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut, 2015, 64, 842-848.	6.1	155
125	Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage. Cancer Immunology Research, 2015, 3, 557-566.	1.6	44
126	The yin and yang of evasion and immune activation in HCC. Journal of Hepatology, 2015, 62, 1420-1429.	1.8	274



#	ARTICLE	IF	CITATIONS
127	Safety and Survival With GVAX Pancreas Prime and <i>Listeria Monocytogenes</i> Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1325-1333.	0.8	490
128	Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: A subgroup analysis from AIO-PK0104. <i>Acta Oncologica</i> , 2015, 54, 993-1000.	0.8	7
129	Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 62, 481-495.	3.6	121
130	Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. <i>Hepatic Oncology</i> , 2015, 2, 39-50.	4.2	10
131	FoxC1: Novel Regulator of Inflammation-Induced Metastasis in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 149, 861-863.	0.6	12
132	Hepatic myeloid-derived suppressor cells in cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 931-940.	2.0	32
133	Immunogenicity of necrotic cell death. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 273-283.	2.4	38
134	Abstract 360: Senescent hepatocytes secrete CCL2 to accelerate liver cancer growth via accumulation of immunosuppressive myeloid cells. <i>Cancer Research</i> , 2015, 75, 360-360.	0.4	1
135	A pilot study of tremelimumab a monoclonal antibody against CTLA-4 in combination with either trans catheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4081-4081.	0.8	15
136	Phase I/II study of ISIS 183750 in combination with irinotecan for advanced solid tumors or colorectal cancer: Final results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 639-639.	0.8	2
137	A multicenter randomized phase II study of NPC-1C (N) in combination with gemcitabine (G) and nab-paclitaxel (A) versus G and A alone in patients with metastatic or locally advanced pancreatic cancer (PC) previously treated with folfirinix (F).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS499-TPS499.	0.8	1
138	A pilot study of AMP-224 a PD-1 inhibitor in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS788-TPS788.	0.8	2
139	Curative treatments and survival benefit in elderly patients with hepatocellular carcinoma: A SEER population-based analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 355-355.	0.8	0
140	A phase I/II study of TRC105 in combination with sorafenib in hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 291-291.	0.8	0
141	A phase 1/2 study of TRC105 in combination with sorafenib in hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4083-4083.	0.8	0
142	Racial/ethnic disparities in hepatocellular carcinoma treatment and survival: Are we making progress?. <i>Journal of Clinical Oncology</i> , 2015, 33, e17591-e17591.	0.8	0
143	Abstract 3166: The role of CD4 T cells in murine model of NASH-promoted HCC. , 2015, , .		0
144	Abstract 875: Risk factors for hepatocellular carcinoma (HCC) by race/ ethnicity in the United States. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
145	Abstract A04: Systemic agonistic anti-CD40 treatment of tumor bearing mice modulates hepatic myeloid suppressive cells and causes immune-mediated liver damage. , 2015, , .		0
146	Abstract B44: The role of CD4 T cells in murine model of NASH-promoted HCC. , 2015, , .		0
147	The Diagnosis and Treatment of Hepatocellular Carcinoma. Deutsches A&#x0308;rzteblatt International, 2014, 111, 101-6.	0.6	66
148	Myeloid-derived suppressor cells in pancreatic cancer: more than a hidden barrier for antitumour immunity?. Gut, 2014, 63, 1690-1691.	6.1	12
149	Response to fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: better 5-year survival or artefactual result of research methodology?. Gut, 2014, 63, 1524.1-1524.	6.1	4
150	Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology, 2014, 60, 1637-1644.	3.6	78
151	Message from the editors. United European Gastroenterology Journal, 2014, 2, 331-332.	1.6	0
152	<scp>IFN</scp>â€³ regulates survival and function of tumorâ€induced <scp>CD</scp>11b<sup>+</sup><scp>G</scp>râ€1<sup>high</sup> myeloid derived suppressor cells by modulating the antiâ€apoptotic molecule <scp>B</scp>cl2a1. European Journal of Immunology, 2014, 44, 2457-2467.	1.6	57
153	pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. BMC Cancer, 2014, 14, 624.	1.1	29
154	Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial. Journal of Clinical Oncology, 2014, 32, 2423-2429.	0.8	397
155	Immunological off-target effects of standard treatments in gastrointestinal cancers. Annals of Oncology, 2014, 25, 24-32.	0.6	51
156	Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions. Hepatology, 2014, 60, 1776-1782.	3.6	210
157	Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncology, The, 2014, 15, 819-828.	5.1	345
158	Immune studies in a mouse model of MET and CAT induced liver tumors. , 2014, 2, .		1
159	Our experts highlight the most important research articles across the spectrum of topics relevant to the field of hepatic oncology. Hepatic Oncology, 2014, 1, 359-360.	4.2	0
160	A pilot study of tremelimumab, a monoclonal antibody against CTLA-4, in combination with either transcatheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2014, 32, e15133-e15133.	0.8	5
161	A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results.. Journal of Clinical Oncology, 2014, 32, 177-177.	0.8	20
162	Tumor Induced Hepatic Myeloid Derived Suppressor Cells Can Cause Moderate Liver Damage. PLoS ONE, 2014, 9, e112717.	1.1	19

#	ARTICLE	IF	CITATIONS
163	TRC105 for the treatment of hepatocellular carcinoma: Preclinical data and preliminary results from two clinical trials evaluating monotherapy and combination with sorafenib.. Journal of Clinical Oncology, 2014, 32, 211-211.	0.8	0
164	Disconnect between earlier presentation patterns and application of curative treatments in HCC.. Journal of Clinical Oncology, 2014, 32, 187-187.	0.8	0
165	In Reply. Deutsches A&#x0308;rzteblatt International, 2014, 111, 464.	0.6	0
166	Personalized Oncology in Interventional Radiology. Journal of Vascular and Interventional Radiology, 2013, 24, 1083-1092.	0.2	27
167	Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 1007-1013.	1.8	154
168	Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. Hepatology, 2013, 57, 1068-1077.	3.6	24
169	Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. Cancer Immunology, Immunotherapy, 2013, 62, 299-307.	2.0	58
170	Hepatocellular Carcinoma from an Immunologic Perspective. Clinical Cancer Research, 2013, 19, 6678-6685.	3.2	89
171	Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the "Arbeitsgemeinschaft Internistische Onkologie" (AIO-PK0104). Gut, 2013, 62, 751-759.	6.1	105
172	Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Stu. International Journal of Cancer, 2013, 132, 1718-1718.	2.3	4
173	Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Annals of Oncology, 2013, 24, 1972-1979.	0.6	120
174	Introductory message from the Editors. United European Gastroenterology Journal, 2013, 1, 6-6.	1.6	0
175	Fibrolamellar hepatocellular carcinoma in the USA, 2000"2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database. United European Gastroenterology Journal, 2013, 1, 351-357.	1.6	93
176	Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000"10. Gut, 2013, 62, 1667-1668.	6.1	61
177	EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. British Journal of Cancer, 2013, 108, 469-476.	2.9	84
178	Peptidases released by necrotic cells control CD8+ T cell cross-priming. Journal of Clinical Investigation, 2013, 123, 4755-4768.	3.9	28
179	Abstract B30: Cross-priming of CD8+ T cells is controlled by dipeptidyl peptidase 3 and thimet oligopeptidase 1 present in necrotic cells.. , 2013, , .		0
180	Effect of the addition of platinum to gemcitabine on outcome in patients with advanced pancreatic cancer who progress on gemcitabine: A comprehensive analysis of published trials.. Journal of Clinical Oncology, 2013, 31, 275-275.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104).. Journal of Clinical Oncology, 2013, 31, 189-189.	0.8	0
182	Abstract 467: Bcl2A1 - an IFN-gamma dependent master switch for the function of CD11b+Gr-1high myeloid derived suppressor cells.. , 2013, , .		0
183	Combination of Conservative and Interventional Therapy Strategies for Intra- and Extrahepatic Cholangiocellular Carcinoma: A Retrospective Survival Analysis. Gastroenterology Research and Practice, 2012, 2012, 1-8.	0.7	16
184	Human CCR4+CCR6+Th17 Cells Suppress Autologous CD8+ T Cell Responses. Journal of Immunology, 2012, 188, 6055-6062.	0.4	48
185	Primary sterile necrotic cells fail to cross-prime CD8<sup>+</sup>T cells. OncoImmunology, 2012, 1, 1017-1026.	2.1	33
186	Human Th17 cells in patients with cancer. OncoImmunology, 2012, 1, 1438-1439.	2.1	13
187	Locally Advanced Cancer of the Esophagus, Current Treatment Strategies, and Future Directions. Frontiers in Oncology, 2012, 2, 52.	1.3	4
188	EASL&EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 908-943.	1.8	5,214
189	Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. Journal of Hepatology, 2012, 56, 1080-1088.	1.8	109
190	EASL&EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. European Journal of Cancer, 2012, 48, 599-641.	1.3	406
191	Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing mice. Journal of Leukocyte Biology, 2012, 92, 1199-1206.	1.5	61
192	Immune Suppression: The Hallmark of Myeloid Derived Suppressor Cells. Immunological Investigations, 2012, 41, 581-594.	1.0	60
193	Cellular Immune Suppressor Mechanisms in Patients with Hepatocellular Carcinoma. Digestive Diseases, 2012, 30, 477-482.	0.8	31
194	Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2012, 18, 2290-2300.	3.2	503
195	S100A9 a new marker for monocytic human myeloid&derived suppressor cells. Immunology, 2012, 136, 176-183.	2.0	176
196	Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: Final analysis of a randomized phase II trial (BINGO).. Journal of Clinical Oncology, 2012, 30, 4032-4032.	0.8	11
197	Comparative analysis of myeloid-derived suppressor cell (MDSC) subsets in patients with gastrointestinal (GI) malignancies.. Journal of Clinical Oncology, 2012, 30, 228-228.	0.8	0
198	Abstract 5412: CCR4+CCR6+Th17 cells suppress autologous CD8+ T cell responses in patients with hepatocellular carcinoma. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
199	Correlation of hand-foot skin reaction (HFS) with treatment efficacy in pancreatic cancer (PC) patients (pts) treated with gemcitabine/capecitabine plus erlotinib: A subgroup analysis from the AIO-PK0104 randomized, cross-over phase III trial in advanced PC.. Journal of Clinical Oncology, 2012, 30, 4023-4023.	0.8	1
200	Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scandinavian Journal of Gastroenterology, 2011, 46, 1092-1098.	0.6	94
201	Myeloid derived suppressor cells in human diseases. International Immunopharmacology, 2011, 11, 802-807.	1.7	374
202	Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood, 2011, 117, 6532-6541.	0.6	205
203	Critical appraisal of clinical practice guidelines for diagnosis and treatment of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1779-1786.	1.4	31
204	Molecular markers of the EGFR pathway in erlotinib-treated patients with advanced pancreatic cancer (APC): Translational analyses of a randomized, cross-over AIO phase III trial.. Journal of Clinical Oncology, 2011, 29, 4047-4047.	0.8	3
205	Bleeding events and eligibility requirements in studies evaluating an antiangiogenic agent in hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2011, 29, 310-310.	0.8	7
206	Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2010, 22, 391-398.	0.8	60
207	Low-dose Cyclophosphamide Treatment Impairs Regulatory T Cells and Unmasks AFP-specific CD4+ T-cell Responses in Patients With Advanced HCC. Journal of Immunotherapy, 2010, 33, 211-218.	1.2	122
208	Erlotinib 150mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the "Arbeitsgemeinschaft Internistische Onkologie"™. Anti-Cancer Drugs, 2010, 21, 94-100.	0.7	28
209	Immune Responses in Hepatocellular Carcinoma. Digestive Diseases, 2010, 28, 150-154.	0.8	38
210	Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study. CardioVascular and Interventional Radiology, 2010, 33, 41-52.	0.9	1,329
211	Immunotherapy of hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2010, 4, 345-353.	1.4	17
212	CD49d Is a New Marker for Distinct Myeloid-Derived Suppressor Cell Subpopulations in Mice. Journal of Immunology, 2010, 185, 203-210.	0.4	101
213	Mycosis Fungoides With Involvement of the Larynx After Liver Transplantation in an Adult. American Journal of Gastroenterology, 2010, 105, 238-240.	0.2	5
214	Fulminant Hepatic Failure due to Chemotherapy-Induced Hepatitis B Reactivation: Role of Rituximab. Zeitschrift Fur Gastroenterologie, 2010, 48, 258-263.	0.2	19
215	Developing better treatments in hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2010, 4, 551-560.	1.4	21
216	Lipopolysaccharide-Mediated Mast Cell Activation Induces IFN- $\gamma$ Secretion by NK Cells. Journal of Immunology, 2010, 185, 119-125.	0.4	32

#	ARTICLE	IF	CITATIONS
217	A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. <i>BMC Cancer</i> , 2010, 10, 209.	1.1	174
218	Radiofrequency ablation for the treatment of HCC –“ Maybe much more than simple tumor destruction?. <i>Journal of Hepatology</i> , 2010, 53, 775-776.	1.8	15
219	215 A PHASE II OPEN LABEL TRIAL EVALUATING SAFETY AND EFFICACY OF A TELOMERASE PEPTIDE VACCINATION IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA. <i>Journal of Hepatology</i> , 2010, 52, S92.	1.8	1
220	566 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ANALYSIS FOR THE DIAGNOSIS OF HCC. <i>Journal of Hepatology</i> , 2010, 52, S225.	1.8	0
221	590 QUALITATIVE ANALYSIS OF INTERNATIONAL GUIDELINES FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA BY THE AGREE INSTRUMENT (APPRAISAL OF GUIDELINES FOR RESEARCH AND) <i>Tj</i> <a href="#">http://dx.doi.org/10.1007/s11067-010-7843-1</a>	1.8	14
222	Molecular therapy of pancreatic cancer. <i>Minerva Endocrinologica</i> , 2010, 35, 27-33.	1.7	7
223	Cetuximab plus cisplatin+5-fluorouracil versus cisplatin+5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. <i>Annals of Oncology</i> , 2009, 20, 1667-1673.	0.6	206
224	Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. <i>Hepatology</i> , 2009, 50, 799-807.	3.6	532
225	Identification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma. <i>Immunology</i> , 2009, 128, 134-140.	2.0	15
226	Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. <i>Immunology</i> , 2009, 128, 141-149.	2.0	111
227	Molecular therapy for the treatment of hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2009, 100, 19-23.	2.9	69
228	A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 4520-4520.	0.8	31
229	Impaired TRAIL-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2008, 15, 200-211.	1.0	20
230	Sorafenib in Advanced Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 378-390.	13.9	12,004
231	Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer. <i>Molecular Oncology</i> , 2008, 2, 349-355.	2.1	30
232	Myeloid-Derived Suppressor Cells in Inflammatory Bowel Disease: A New Immunoregulatory Pathway. <i>Gastroenterology</i> , 2008, 135, 871-881.e5.	0.6	262
233	A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells. <i>Gastroenterology</i> , 2008, 135, 234-243.	0.6	722
234	Complement 5a Receptor Inhibition Improves Renal Allograft Survival. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 2302-2312.	3.0	112

#	ARTICLE	IF	CITATIONS
235	Immunotherapy of HCC. Reviews on Recent Clinical Trials, 2008, 3, 31-39.	0.4	54
236	Tumour-Associated Transcripts and EGFR Deletion Variants in Colorectal Cancer in Primary Tumour, Metastases and Circulating Tumour Cells. Analytical Cellular Pathology, 2008, 30, 463-471.	0.7	1
237	Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells. Cellular Oncology, 2008, 30, 463-71.	1.9	17
238	Necrotic Tumor Cell Death In Vivo Impairs Tumor-Specific Immune Responses. Journal of Immunology, 2007, 178, 1573-1580.	0.4	44
239	Participation in screening colonoscopy in first-degree relatives from patients with colorectal cancer. Annals of Oncology, 2007, 18, 1518-1522.	0.6	34
240	[370] IMPAIRED DENDRITIC CELLS IN TUMORS OF PATIENTS WITH HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2007, 46, S144.	1.8	0
241	Peptide- $\beta$ 2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells. Immunology, 2007, 122, 90-97.	2.0	11
242	Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viraemia. European Journal of Clinical Investigation, 2007, 37, 54-64.	1.7	36
243	A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results. Journal of Clinical Oncology, 2007, 25, 4598-4598.	0.8	58
244	Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. Hepatobiliary and Pancreatic Diseases International, 2007, 6, 259-66.	0.6	41
245	Tumor-associated gene expression in disseminated tumor cells correlates with disease progression and tumor stage in colorectal cancer. Anticancer Research, 2007, 27, 1823-32.	0.5	15
246	Immune based therapies in cancer. Histology and Histopathology, 2007, 22, 687-96.	0.5	22
247	Immunotherapy of hepatocellular carcinoma. Journal of Hepatology, 2006, 45, 868-878.	1.8	69
248	Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: A randomised trial. European Journal of Surgical Oncology, 2006, 32, 201-207.	0.5	37
249	Genetically Induced Pancreatic Adenocarcinoma Is Highly Immunogenic and Causes Spontaneous Tumor-Specific Immune Responses. Cancer Research, 2006, 66, 508-516.	0.4	40
250	Cytotoxic CD4+ T cells in viral hepatitis. Journal of Viral Hepatitis, 2006, 13, 505-514.	1.0	130
251	Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2006, 12, 3275.	1.4	99
252	Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. British Journal of Cancer, 2005, 92, 1862-1868.	2.9	176

#	ARTICLE	IF	CITATIONS
253	Hepatocellular carcinoma occurring after successful treatment of childhood cancer with high dose chemotherapy and radiation. <i>Gut</i> , 2005, 54, 732-732.	6.1	20
254	Increased Populations of Regulatory T Cells in Peripheral Blood of Patients with Hepatocellular Carcinoma. <i>Cancer Research</i> , 2005, 65, 2457-2464.	0.4	561
255	MHC-Ig Dimeric Molecules. , 2005, , 227-238.		0
256	Spontaneous Tumor-Specific Humoral and Cellular Immune Responses to NY-ESO-1 in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 4332-4341.	3.2	132
257	Maintenance of Peritoneal B-1a Lymphocytes in the Absence of the Spleen. <i>Journal of Immunology</i> , 2004, 173, 197-204.	0.4	24
258	IKK $\beta$ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer. <i>Cell</i> , 2004, 118, 285-296.	13.5	2,277
259	393 Impaired trail-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2004, 40, 117.	1.8	0
260	Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. <i>International Journal of Cancer</i> , 2003, 103, 205-211.	2.3	195
261	Representational difference analysis based identification and full-length sequencing of the B10-gene of the aldo-keto reductase family 1 clearly overexpressed in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2003, 38, 97-98.	1.8	1
262	CD40 in hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 113-114.	0.8	2
263	1874 Usefulness of aortic valve resistance in assessment of haemodynamic severity in aortic stenosis. <i>European Heart Journal</i> , 2003, 24, 359.	1.0	0
264	Immunotherapy of hepatocellular carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2002, 2, 123-133.	1.4	18
265	Development and Use of Multimeric Major Histocompatibility Complex Molecules. <i>Vaccine Journal</i> , 2002, 9, 216-220.	3.2	10
266	Stat3 and NF- $\kappa$ B activation prevents apoptosis in pancreatic carcinogenesis. <i>Gastroenterology</i> , 2002, 123, 2052-2063.	0.6	155
267	Peptide $\beta$ 2-microglobulin $\alpha$ MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC $\beta$ Ig complexes. <i>Journal of Immunological Methods</i> , 2002, 271, 125-135.	0.6	42
268	Generation of activated and antigen-specific T cells with cytotoxic activity after co-culture with dendritic cells. <i>Cancer Immunology, Immunotherapy</i> , 2002, 51, 25-32.	2.0	23
269	Monitoring Antigen-Specific T Cells Using MHC-Ig Dimers. , 2001, Chapter 17, Unit 17.2.		14
270	Increased Activated Human T Cell Lymphotropic Virus Type I (HTLV $\beta$ ) Tax1 $\beta$ 19 $\beta$ Specific Memory and Effector CD8 $\beta$ Cells in Patients with HTLV $\beta$ Associated Myelopathy/Tropical Spastic Paraparesis: Correlation with HTLV $\beta$ Provirus Load. <i>Journal of Infectious Diseases</i> , 2001, 183, 197-205.	1.9	128



#	ARTICLE	IF	CITATIONS
271	Cancer Vaccines. <i>Journal of Clinical Oncology</i> , 1999, 17, 1047-1047.	0.8	139
272	An Algorithm for Evaluating Human Cytotoxic T Lymphocyte Responses to Candidate AIDS Vaccines. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1021-1034.	0.5	15
273	Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. <i>Journal of Immunology</i> , 1999, 162, 1765-71.	0.4	105
274	Nitric oxide downregulates tumour necrosis factor mRNA in RAW 264.7 cells. <i>Research in Immunology</i> , 1998, 149, 139-150.	0.9	30
275	Enhanced Tumor Protection by Granulocyte-Macrophage Colony-Stimulating Factor Expression at the Site of an Allogeneic Vaccine. <i>Human Gene Therapy</i> , 1998, 9, 835-843.	1.4	89
276	A Phase I Clinical Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected with the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma. The Johns Hopkins Oncology Center, Baltimore, Maryland. <i>Human Gene Therapy</i> , 1998, 9, 1951-1971.	1.4	78
277	Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8+ T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 7568-7573.	3.3	241
278	Cancer Vaccines. <i>Current Protocols in Human Genetics</i> , 1997, 14, Unit 13.8.	3.5	0
279	Suppression of tumor necrosis factor- $\alpha$ production by interleukin-10 is enhanced by cAMP-elevating agents. <i>European Journal of Pharmacology</i> , 1997, 321, 231-239.	1.7	32
280	Endogenous Adenosine Curtails Lipopolysaccharide- $\alpha$ Stimulated Tumour Necrosis Factor Synthesis. <i>Scandinavian Journal of Immunology</i> , 1997, 45, 132-139.	1.3	81
281	Altered expression of the Ca <sup>2+</sup> -binding protein S100A1 in human cardiomyopathy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1996, 1313, 253-257.	1.9	149
282	Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor- $\alpha$ synthesis. <i>European Journal of Pharmacology</i> , 1996, 299, 229-233.	1.7	16
283	Graves' disease and sarcoidosis in a patient with minimal-change glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 860-862.	0.4	27
284	Factitious hypertensive crisis (Munchhausen syndrome). <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 893-894.	0.4	5
285	Troponin T: A diagnostic marker for myocardial infarction and minor cardiac cell damage. <i>European Heart Journal</i> , 1996, 17, 3-8.	1.0	132
286	Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication. <i>Aids</i> , 1995, 9, 1137-1144.	1.0	33
287	The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF- $\alpha$ and nitric oxide. <i>International Journal of Immunopharmacology</i> , 1995, 17, 605-610.	1.1	31
288	Checkpoint Inhibitors Modulate Plasticity of Innate Lymphoid Cells in Peripheral Blood of Patients With Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4